1 male Expedited covid 19, CORONAVIBUS (5 2.1 adenocarcinoma left 0.7 pT1 well differentiated who pre procedure and pre operative covid 19 Canada (19 2.1 adenocarcinoma left 0.7 pT1 well differentiated 4 female expedited covid 19 Canada (19 2.1 adenocarcinoma left 0.7 pT1 well differentiated 4 female expedited covid 19 Canada (19 2.1 adenocarcinoma right 0.1 pT1 moderately differentiated 10 male pre procedure and pre operative covid 19 Canada (19 2.1 adenocarcinoma left 0.2 pT2 covid-19 PCR nasopharynx (bio-ref) C 30.12 adenocarcinoma left 0.5 pT2 covid-19 PCR nasopharynx (bio-ref) C 30.12 adenocarcinoma left 0.7 pT1 well differentiated 10 male pre procedure and pre operative covid 0.2 pt adenocarcinoma left 0.2 pT2 covid-19 PCR nasopharynx (bio-ref) C 30.12 adenocarcinoma left 0.7 pT1 well differentiated 10 male pre procedure and pre operative covid 0.2 pt adenocarcinoma left 0.2 pT1 well differentiated 11 female pre procedure and pre operative covid 0.2 pt adenocarcinoma left 0.2 pT1 well differentiated 13 female pre procedure and pre operative covid 0.2 pt adenocarcinoma left 0.4 pT1 moderately differentiated 13 female 0.2 pt procedure and pre operative covid 0.2 pt adenocarcinoma left 0.4 pT1 moderately differentiated 15 male 0.2 pt procedure and pre operative 0.2 pt adenocarcinoma left 0.4 pT1 moderately differentiated 15 male 0.2 pt procedure and pre operative 0.2 pt	GERD GERD Ulcerative Colitis GERD GERD GERD GERD GERD GERD GERD GERD
4 female expedited covid19 (2.23 a Intranuous) adenocarcinoma left properties of the female concavirus (sars cov 2 access labs), p. 21.5 adenocarcinoma right procedure and pre operative covid 2.39 adenocarcinoma left procedure and pre operative covid 2.40 adenocarcinoma left procedure and pre operative covid procedure and p	GERD Ulcerative Colitis GERD GERD GERD GERD Type II Diabetes Mellitus Type II Diabetes Mellitus GERD GERD GERD GERD GERD Type II Diabetes Mellitus GERD GERD GERD GERD GERD GERD GERD GERD Ulcerative Colitis GERD Type II Diabetes Mellitus
4 female expedited covid19 22.38 Intramucosal adenocarcinoma right 1 pT3 moderately differentiated coronavirus (sars cov 2 access labs), p 21.5 adenocarcinoma right 2.5 pT2 moderately differentiated 10 male per procedure and pre operative covid 24.1 mixed neuroendocrine carcinoma- aleft 25.5 pT3 moderately differentiated 11 female pre procedure and pre operative covid 23.9 adenocarcinoma left pre procedure and pre operative covid 25.3 adenocarcinoma left pre procedure and pre operative covid 25.3 adenocarcinoma left pre procedure and pre operative covid 25.3 adenocarcinoma left pre procedure and pre operative covid 25.3 adenocarcinoma left pre procedure and pre operative covid 25.3 adenocarcinoma left pre procedure and pre operative covid 25.3 adenocarcinoma left pre procedure and pre operative covid 25.3 adenocarcinoma left pre procedure and pre operative covid 25.3 adenocarcinoma left pre procedure and pre operative covid 24.13 adenocarcinoma left pre procedure and pre operative covid 24.13 adenocarcinoma left pre procedure and pre operative covid 24.13 adenocarcinoma left pre procedure and pre operative covid 24.13 adenocarcinoma left pre procedure and pre operative covid 24.13 adenocarcinoma left pre procedure and pre operative covid 24.13 adenocarcinoma left pre procedure and pre operative covid 25.5 adenocarcinoma left pre procedure and pre operative covid 25.5 adenocarcinoma left pre procedure and pre operative covid 25.5 adenocarcinoma left pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left pre procedure and pre operative covid 19.75 signet-ring cell carcinoma left pre procedure and pre operative covid 19.	GERD Ulcerative Colitis GERD GERD GERD GERD Type II Diabetes Mellitus Type II Diabetes Mellitus GERD GERD GERD GERD GERD Type II Diabetes Mellitus GERD GERD GERD GERD GERD GERD GERD GERD Ulcerative Colitis GERD Type II Diabetes Mellitus
9 male expetited covid19 PCR nasopharynx (blor-ef). C 30.12 adenocarcinoma left 2.5 pT2 9 male expetited covid19 2 26.96 adenocarcinoma right 3.5 pT3 moderately differentiated 10 male pre procedure and pre operative covid 24.1 mixed neuroendocrine carcinoma-ade left 11 female pre procedure and pre operative covid 25.9 adenocarcinoma left 15 pT4 moderately differentiated 12 male pre procedure and pre operative covid 27.5 adenocarcinoma left 15 pT4 moderately differentiated 13 female pre procedure and pre operative covid 27.5 adenocarcinoma left 0.4 pT1 moderately differentiated 15 male 2019 coronavirus, Coronavirus (sars cov. 2 access labs), e 26.93 adenocarcinoma left 0.4 pT1 moderately differentiated 17 male coronavirus (sars cov. 2 access labs), e 28.12 adenocarcinoma left 1 pT1 moderately differentiated 18 male coronavirus (sars cov. 2 access labs), e 28.12 adenocarcinoma left 1 pT1 moderately differentiated 19 female CCRR rapid covid19, covid-19 PCR na a 25.5 adenocarcinoma left 5.5 pT3 moderately differentiated 21 female for 2019 coronavirus, expedited covid 19.77 signet-ring cell carcinoma left 5.5 pT3 moderately differentiated 24 male two 2019 coronavirus, pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left 3 pT4 poorty differentiated 25 female two pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left 3 pT4 poorty differentiated 25 male pre procedure and pre operative covid 19.23 adenocarcinoma left 1.8 pT2 well differentiated 26 male covid-19 PCR nasopharynx (BIOREF) 28.94 adenocarcinoma left 1.8 pT2 well differentiated 27 male pre procedure and pre operative covid 19.24 adenocarcinoma left 1.8 pT2 well differentiated 29 male pre procedure and pre operative covid 19.24 adenocarcinoma left 1.8 pT2 well differentiated 29 male pre procedure and pre operative covid 19.25 adenocarcinoma left 1.8 pT2 well differentiated 29 male pre procedure and pre operative covid 19.25 adenocarcinoma left 1.8 pT2 moderately differentiated 29.25 adenocarcinoma left 1.8 pT2 modera	Ulcerative Colitis GERD GERD GERD GERD Type II Diabetes Mellitus Type II Diabetes Mellitus GERD GERD GERD GERD GERD GERD GERD GER
9 male expedited covid19 26.96 adenocarcinoma right 3.5 pT3 moderately differentiated 10 male pre procedure and pre operative covid 24.1 mixed neuroendocrine carcinoma-ade left pre procedure and pre operative covid 23.9 adenocarcinoma left pre procedure and pre operative covid 23.9 adenocarcinoma left 15 pT4 moderately differentiated 13 female pre procedure and pre operative covid 37.5 adenocarcinoma left 0.4 pT1 moderately differentiated 15 male 2019 coronavirus, coronavirus (sars cc 24.13 adenocarcinoma left 3.5 pT2 moderately differentiated 16 female two pre procedure and pre operative covid 25.99 adenocarcinoma left 1 pT1 moderately differentiated 17 male coronavirus (sars cov 2 access labs), p 26.89 adenocarcinoma left 1 pT1 moderately differentiated 18 male coronavirus (sars cov 2 access labs), p 28.12 adenocarcinoma left 1 pT1 moderately differentiated 19 female Coronavirus, capacitic covid-19 PCR na cohoracinoma left 1 pT1 moderately differentiated 19 female Coronavirus, expedited cov 24.2 adenocarcinoma left 5.5 pT3 moderately differentiated 19 female Coronavirus, expedited cov 24.2 adenocarcinoma left 5.5 pT3 moderately differentiated 19 female coronavirus, expedited cov 24.2 adenocarcinoma left 5.5 pT3 moderately differentiated 19 female coronavirus, procedure and pre operative covid 19.77 signet-ring cell carcinoma left 5.5 pT3 moderately differentiated 19 female two pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left 1.3 pT4 poorty differentiated 19.77 male pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left 0.8 moderately differentiated 25 female pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left 0.8 moderately differentiated 19.78 male pre procedure and pre operative covid 19.25 adenocarcinoma left 0.8 moderately differentiated 19.78 male pre procedure and pre operative covid 19.25 adenocarcinoma left 0.4 pT3 well differentiated 19.78 male pre procedure and pre operative covid 19.25 adenocarcinoma left 0.4 pT3 moderately dif	GERD GERD GERD GERD Type II Diabetes Mellitus Type II Diabetes Mellitus GERD GERD GERD GERD GERD GERD GERD GER
10 male pre procedure and pre operative covid 24.1 mixed neuroendocrine carcinoma-ade left pT well differentiated 12 male pre procedure and pre operative covid 23.9 adenocarcinoma left 15 pT4 moderately differentiated 13 female pre procedure and pre operative covid 25 adenocarcinoma left 0.4 pT1 moderately differentiated 15 male 2019 coronavirus (sars cov 2 access labs), p 26.89 adenocarcinoma left 3.5 pT2 moderately differentiated 16 female two pre procedure and pre operative covid 25.99 adenocarcinoma left 1 pT1 moderately differentiated 18 male coronavirus (sars cov 2 access labs), p 26.89 adenocarcinoma left 1 pT1 moderately differentiated 19 female CCIRR rapid covid19, covid-19 PCR na 25.60 adenocarcinoma left 1 pT1 moderately differentiated 19 female CCIRR rapid covid19, covid-19 PCR na 25.60 adenocarcinoma left 5.5 pT3 moderately differentiated 21 female pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left 5.5 pT3 moderately differentiated 23 female pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left 5.5 pT3 moderately differentiated 25 female wo 2019 coronavirus, preprocedure 29.7 adenocarcinoma left 5.5 pT3 moderately differentiated 25 female wo 2019 coronavirus, preprocedure 29.7 adenocarcinoma left 3 pT4 poorly differentiated 25 female wo 2019 coronavirus, preprocedure 25.7 adenocarcinoma left 3 pT4 poorly differentiated 25 female work pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left 3.5 pT3 moderately differentiated 25 female work preprocedure and pre operative covid 19.78 signet-ring cell carcinoma left 4.3 pT3 well differentiated 26 male covid-19 PCR nasopharynx (BIOREF) 29.7 adenocarcinoma left 18.8 pT2 well differentiated 27 male pre procedure and pre operative covid 32.2 adenocarcinoma left 18.8 pT2 moderately differentiated 30 male pre procedure and pre operative covid 30.2 adenocarcinoma left 18.8 pT2 moderately differentiated 31 female pre procedure and pre operative covid 30.8 adenocarcinoma left 9.5 pT3 well differen	GERD GERD GERD Type II Diabetes Mellitus Type II Diabetes Mellitus GERD GERD GERD GERD GERD GERD Ulcerative Colitis GERD Type II Diabetes Mellitus
12 male pre procedure and pre operative covid 26 adenocarcinoma left 0.4 pT1 moderately differentiated 15 male 2019 coronavirus, coronavirus (sars cc 24.13 adenocarcinoma left 3.5 pT2 moderately differentiated 16 female two pre procedure and pre operative covid 25.99 adenocarcinoma right 4 pT4 moderately differentiated 17 male coronavirus (sars cov 2 access labs), p 26.89 adenocarcinoma left 1 pT1 moderately differentiated 18 male coronavirus (sars cov 2 access labs), p 26.89 adenocarcinoma left 1 pT1 moderately differentiated 19 female CCIRH rapid covid19, covid-19 PCR na 25.6 adenocarcinoma left 5.5 pT3 moderately differentiated 21 female pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left 3.5 pT3 moderately differentiated 23 female pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left 3.74 poorly differentiated 25 female two pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left 0.8 moderately differentiated 25 female two pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left 0.8 moderately differentiated 25 female covid-19 PCR na 3.74 poorly differentiated 25 female covid-19 PCR nasopharynx (BIOREF) 28.94 adenocarcinoma left 0.8 moderately differentiated 26 male covid-19 PCR nasopharynx (BIOREF) 28.94 adenocarcinoma left 0.8 moderately differentiated 27 male pre procedure and pre operative covid 32.2 adenocarcinoma left 0.8 moderately differentiated 27 male pre procedure and pre operative covid 32.2 adenocarcinoma right 0.4 pT3 well differentiated 31 female pre procedure and pre operative covid 32.2 adenocarcinoma right 0.4 pT3 well differentiated 31 female pre procedure and pre operative covid 32.2 adenocarcinoma left 1.8 pT2 moderately differentiated 32 female pre procedure and pre operative covid 32.2 adenocarcinoma right 0.4 pT3 well differentiated 34 male pre procedure and pre operative covid 32.2 adenocarcinoma left 0.4 moderately differentiated 35 female pre procedure and pre operative covid 32.2 adenocarcinoma le	GERD GERD Type II Diabetes Mellitus Type II Diabetes Mellitus GERD GERD GERD Ulcerative Colitis GERD Type II Diabetes Mellitus
13 female pre procedure and pre operative covid 37.5 adenocarcinoma left 3.5 pT2 moderately differentiated 15 male 2019 coronavirus, (sars cu 2 41.13 adenocarcinoma left 3.5 pT2 moderately differentiated 17 male coronavirus (sars cov 2 access labs), p 26.89 adenocarcinoma left 1 pT1 moderately differentiated 18 male coronavirus (sars cov 2 access labs), p 26.89 adenocarcinoma left 1 pT1 moderately differentiated 18 male coronavirus (sars cov 2 access labs), p 26.89 adenocarcinoma left 1 pT1 moderately differentiated 19 female CCIRH rapid covid19, covid-19 PCR na 25.6 adenocarcinoma left 5.5 pT3 moderately differentiated 21 female CCIRH rapid covid19, covid-19 PCR na 25.6 adenocarcinoma left 5.5 pT3 moderately differentiated 21 female procedure and pre operative covid 24.2 adenocarcinoma left 5.5 pT3 moderately differentiated 23 female per procedure and pre operative covid 19.77 signet-ring cell carcinoma left 3 pT4 poorly differentiated 24 male two 2019 coronavirus, pre procedure 29.7 adenocarcinoma left 3 pT4 poorly differentiated 25 female two pre procedure and pre operative covid 29.77 signet-ring cell carcinoma left 3.5 pT3 moderately differentiated 26 female covid-19 PCR nasopharnyx (BIOREF) 18.94 adenocarcinoma left 0.8 moderately differentiated 27 male pre procedure and pre operative covid 32.2 adenocarcinoma left 0.8 moderately differentiated 27 male pre procedure and pre operative covid 32.2 adenocarcinoma left 1.8 pT2 moderately differentiated 30 male pre procedure and pre operative covid 30.2 adenocarcinoma left 1.8 pT2 moderately differentiated 31 female pre procedure and pre operative covid 30.2 adenocarcinoma left 1.8 pT2 moderately differentiated 31 female pre procedure and pre operative covid 30.2 adenocarcinoma left 3.4 pT2 moderately differentiated 34 female pre procedure and pre operative covid 30.2 adenocarcinoma left 0.4 moderately differentiated 35	GERD GERD Type II Diabetes Mellitus Type II Diabetes Mellitus GERD GERD GERD Ulcerative Colitis GERD Type II Diabetes Mellitus
16 female two pre procedure and pre operative c 25.99 adenocarcinoma in right 4 pT4 moderately differentiated 17 male coronavirus (sars cov 2 access labs), p 26.89 adenocarcinoma left 1 pT1 moderately differentiated 18 male coronavirus (sars cov 2 access labs), e 26.22 adenocarcinoma left moderately differentiated 19 female CCIRH rapid covid19, covid-19 PCR na 25.6 adenocarcinoma left 5.5 pT3 moderately differentiated 21 female four 2019 coronavirus, expedited cov 24.2 adenocarcinoma left 5.5 pT3 moderately differentiated 23 female per procedure and pre operative covid 19.77 signet-ring cell carcinoma left 3 pT4 poorly differentiated 24 male two 2019 coronavirus, pre procedure 29.7 adenocarcinoma left moderately differentiated 25 female covid-19 PCR nasopharynx (BIOREF) 28.94 adenocarcinoma left moderately differentiated 25 female covid-19 PCR nasopharynx (BIOREF) 28.94 adenocarcinoma left 0.8 moderately differentiated 27 male pre procedure and pre operative covid 32.2 adenocarcinoma left 0.8 moderately differentiated 27 male pre procedure and pre operative covid 32.2 adenocarcinoma left 0.8 moderately differentiated 27 male pre procedure and pre operative covid 32.2 adenocarcinoma left 18 pT2 29 male pre procedure and pre operative covid 36.78 adenocarcinoma left 18 pT2 29 male pre procedure and pre operative covid 36.78 adenocarcinoma left 18 pT2 30 male pre procedure and pre operative covid 30.2 adenocarcinoma left 31 female pre procedure and pre operative covid 31.6 adenocarcinoma left 32 female pre procedure and pre operative covid 35.5 adenocarcinoma left 36 female pre procedure and pre operative covid 36.78 adenocarcinoma left 37 female covid-19 pCR nasopharynx (BIOREF) 23.6 adenocarcinoma left 3.4 pT2 moderately differentiated 35 female expedited covid 9 23.68 neuroendocrine carcinoma left 3.4 pT2 moderately differentiated 36 female expedited covid 39 23.64 adenocarcinoma left 3.4 pT2 moderately differentiated 36 female expedited covid 39 23.64 adenocarcinoma left 3.5 pT3 poorly differentiated 36 female	GERD Type II Diabetes Mellitus Type II Diabetes Mellitus GERD GERD GERD Ulcerative Colitis GERD Type II Diabetes Mellitus
17 male coronavirus (sars cov 2 access labs), p 26.89 adenocarcinoma left moderately differentiated 28 male coronavirus (sars cov 2 access labs), e 28.12 adenocarcinoma left moderately differentiated 19 female CCIRH rapid covid19, covid-19 PCR na 25.6 adenocarcinoma left 5.5 pT3 moderately differentiated 21 female four 2019 coronavirus, expedited cov 24.2 adenocarcinoma left 5.5 pT3 moderately differentiated 23 female per procedure and pre operative covid 19.77 signet-ring cell carcinoma left 3 pT4 poorly differentiated 24 male two 2019 coronavirus, pre procedure 29.7 adenocarcinoma left 9.5 female two pre procedure and pre operative covid 29.73 signet-ring cell carcinoma left 9.5 female word-19.72 female pre operative covid 29.73 adenocarcinoma left 9.5 female pre procedure and pre operative covid 32.2 adenocarcinoma left 9.5 male pre procedure and pre operative covid 32.2 adenocarcinoma left 9.5 male pre procedure and pre operative covid 32.2 adenocarcinoma left 1.8 pT2 1.5 male pre procedure and pre operative covid 32.2 adenocarcinoma left 1.8 pT2 1.5 male pre procedure and pre operative covid 30.2 adenocarcinoma left 1.8 pT2 1.5 moderately differentiated 1.5 pT3 moderately differentiated 1.5 pT3 moderately differentiated 1.5 pT4 moderately differentiated 1.5 pT5 moderately differentiated 1.5 pT5 moderately differentiated 1.5 pT5 moderately differentiated 1.5 pT6 moderately differentiated 1.5 pT6 moderately differentiated 1.5 pT6 moderately differentiated 1.5 pT7 moderately	Type II Diabetes Mellitus Type II Diabetes Mellitus GERD GERD GERD Ulcerative Colitis GERD Type II Diabetes Mellitus
18 male coronavirus (sars cov 2 access labs), e 28.12 adenocarcinoma left 5.5 pT3 moderately differentiated 21 female four 2019 coronavirus, expedited cov 24.2 adenocarcinoma left 5.5 pT3 moderately differentiated 23 female pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left 3 pT4 poorly differentiated 24 male two 2019 coronavirus, per procedure 27 adenocarcinoma left 3 pT4 poorly differentiated 25 female wo pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left moderately differentiated 25 female covid-19 PCR nasopharynx (BIOREF) 28.94 adenocarcinoma left 0.8 moderately differentiated 27 male pre procedure and pre operative covid 2.2 adenocarcinoma left 0.8 moderately differentiated 27 male pre procedure and pre operative covid 3.2 adenocarcinoma left 1.8 pT2 well differentiated 28 female expedited covid-19 PCR nasopharynx (BIOREF) 29.1 mucinous adenocarcinoma left 1.8 pT2 well differentiated 29.1 mucinous adenocarcinoma left 1.8 pT2 well differentiated 30 male pre procedure and pre operative covid 36.78 adenocarcinoma left 1.8 pT2 well differentiated 21.5 female pre procedure and pre operative covid 31.6 adenocarcinoma left 31.6 adenocarcinoma left 31.6 adenocarcinoma left 31.6 adenocarcinoma left 32.7 female pre procedure and pre operative covid 31.16 adenocarcinoma left 34.9 pT2 moderately differentiated 33 female bre procedure and pre operative covid 25.1 squamous cell carcinoma left 34.0 pT2 moderately differentiated 35.6 female expedited covid-19 23.68 neuroendocrinoma left 34.0 pT2 moderately differentiated 36.6 female expedited covid-19 23.68 neuroendocrinoma left 37.6 female expedited covid-19 23.6 adenocarcinoma left	Type II Diabetes Mellitus Type II Diabetes Mellitus GERD GERD GERD Ulcerative Colitis GERD Type II Diabetes Mellitus
21 female four 2019 coronavirus, expedited cov 24.2 adenocarcinoma left 3.5 pT3 moderately differentiated 23 female pre procedure and pre operative covid 19.77 signet-ring cell carcinoma left 3.7 pT4 poorly differentiated 25 female two pre procedure and pre operative covid 25 adenocarcinoma left 4.3 pT3 moderately differentiated 26 male covid-19.PCR nasopharynx (BIOREF) 28.94 adenocarcinoma left 0.8 moderately differentiated 27 male pre procedure and pre operative covid 3.2.2 adenocarcinoma left 0.8 moderately differentiated 28 female expedited covid-19.PCR nasopharynx (BIOREF) 29.1 mucinous adenocarcinoma left 1.8 pT2 legal expedited covid-19.PCR nasopharynx (BIOREF) 29.1 mucinous adenocarcinoma left 1.8 pT2 legal expedited covid-19.PCR adenocarcinoma left 1.8 pT2 legal expedited pre procedure and pre operative covid 30.2 adenocarcinoma left 1.8 pT2 legal expedited pre procedure and pre operative covid 30.2 adenocarcinoma left 1.8 pT2 legal expedited pre procedure and pre operative covid 31.16 adenocarcinoma left 1.8 pT2 moderately differentiated 1.8 female legal expedited covid-19. Squamous cell carcinoma left 1.8 pT2 moderately differentiated 1.8 female expedited covid-19. Squamous cell carcinoma left 1.8 pT2 moderately differentiated 1.8 female expedited covid-19. Squamous cell carcinoma left 1.5 pT1 moderately differentiated 1.8 female expedited covid-19. Squamous cell carcinoma left 1.5 pT1 moderately differentiated 1.8 female expedited covid-19. Squamous cell carcinoma left 1.5 pT1 moderately differentiated 1.8 female expedited covid-19. Coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma left 1.5 pT1 moderately differentiated 1.8 female expedited covid-19. Coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma left 1.5 pT3 moderately differentiated 1.8 female expedited cov	Type II Diabetes Mellitus GERD GERD GERD GERD Ulcerative Colitis GERD Type II Diabetes Mellitus
23 female two 2019 coronavirus, pre procedure 29.7 adenocarcinoma left 3 pT4 poorly differentiated moderately differentiated 25 female two 2019 coronavirus, pre procedure 29.7 adenocarcinoma left 3.3 pT3 moderately differentiated 25 female covid-19 PCR nasopharynx (BIOREF) 28.94 adenocarcinoma left 0.8 moderately differentiated 27 male pre procedure and pre operative covid 32.2 adenocarcinoma left 0.8 moderately differentiated 27 male pre procedure and pre operative covid 32.2 adenocarcinoma left 1.8 pT2 pmale pre procedure and pre operative covid 36.78 adenocarcinoma left 1.8 pT2 pmale pre procedure and pre operative covid 36.78 adenocarcinoma left 1.8 pT2 pmale pre procedure and pre operative covid 30.2 adenocarcinoma left 1.8 pT2 pmale pre procedure and pre operative covid 30.2 adenocarcinoma left 1.8 pT2 pmale pre procedure and pre operative covid 30.2 adenocarcinoma left 1.8 pT2 pmale pre procedure and pre operative covid 30.2 adenocarcinoma left 1.8 pT2 pmale pre procedure and pre operative covid 30.2 adenocarcinoma left 1.8 pT2 pmale pre procedure and pre operative covid 30.5 adenocarcinoma left 1.8 pT2 pmale pre procedure and pre operative covid 23.6 adenocarcinoma left 1.8 pT2 pmale pre procedure and pre operative covid 25.6 adenocarcinoma left 1.8 pT2 pmale pre procedure and pre operative covid 25.5 squamous cell carcinoma left 1.8 pT2 pmale pre procedure and pre operative covid 25.1 squamous cell carcinoma left 1.8 pT2 pmale pre procedure and pre operative covid 25.1 squamous cell carcinoma left 1.8 pT2 pmale pre procedure and pre operative covid 25.2 squamous cell carcinoma left 1.8 pT3 poorly differentiated 1.8 pre procedure and pre operative covid 25.1 squamous cell carcinoma left 1.8 pT1 pmale pre procedure and pre operative covid 25.1 squamous cell carcinoma left 1.8 pT1 pmale covid 1.8 pp. pmale 25.1 squamous cell carcinoma left 1.8 pT1 pmale covid 1.8 pp. pmale 25.1 squamous cell carcinoma left 1.8 pT1 pmale covid 1.8 pp. pmale 25.3 adenocarcinoma left 1.8 pT1 pmale covid 1.8 pp. pmale 25.3 ad	Type II Diabetes Mellitus GERD GERD GERD GERD Ulcerative Colitis GERD Type II Diabetes Mellitus
24 male two 2019 coronavirus, pre procedure and pre operative covid-19 PCR nasopharynx (BIOREF) 28,94 adenocarcinoma left 4.3 pT3 moderately differentiated 26 male covid-19 PCR nasopharynx (BIOREF) 28,94 adenocarcinoma left 0.8 moderately differentiated 27 male pre procedure and pre operative covid 32.2 adenocarcinoma right 4.2 pT1 well differentiated 28 female expedited covid-19 PCR nasopharynx (BIOREF) 29.1 mucinous adenocarcinoma left 1.8 pT2 29 male pre procedure and pre operative covid 36.78 adenocarcinoma right 0.4 pT3 well differentiated 30 male pre procedure and pre operative covid 30.2 adenocarcinoma left 1.8 pT2 4.5 pT2 moderately differentiated 31 female pre procedure and pre operative covid 31.6 adenocarcinoma left 32 female pre procedure and pre operative covid 31.6 adenocarcinoma left moderately differentiated 32 female three pre procedure and pre operative covid 31.5 adenocarcinoma left 33 female three pre procedure and pre operative covid 31.5 squamous cell carcinoma left 0.4 moderately differentiated 35 female expedited covid-19 23.68 neuroendocrine carcinoma left 0.4 moderately differentiated 35 female expedited covid-19 23.68 neuroendocrine carcinoma right 6 pT3 poorly differentiated 36 female expedited covid-19 23.68 neuroendocrine carcinoma right 6 pT3 poorly differentiated 37 female coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma left 5.5 pT3 well differentiated 38 female expedited covid-19 23.63 adenocarcinoma left 5.5 pT3 well differentiated 40 male two coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma left 5.5 pT3 well differentiated 41 male two coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma left 0.3 pT2 moderately differentiated 42 female coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma left 0.7 pT2 moderately differentiated 42 female coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma left 0.7 pT2 moderately differentiated 42 female coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma left 0.7 pT2 moderately differentiated 42 female coronavir	GERD GERD GERD Ulcerative Colitis GERD Type II Diabetes Mellitus
26 male covid-19 PCR nasopharynx (BIOREF) 28.94 adenocarcinoma right 4.2 pT1 well differentiated pre procedure and pre operative covid 32.2 adenocarcinoma right 4.2 pT1 well differentiated 18 pT2 pm procedure and pre operative covid 36.78 adenocarcinoma right 0.4 pT3 well differentiated 18 pT2 pm procedure and pre operative covid 36.78 adenocarcinoma right 0.4 pT3 well differentiated 19.1 pm procedure and pre operative covid 30.2 adenocarcinoma right 0.4 pT3 well differentiated 19.2 female pre procedure and pre operative covid 31.6 adenocarcinoma right 4.5 pT2 moderately differentiated 19.2 female pre procedure and pre operative covid 23.6 adenocarcinoma right 4.5 pT2 moderately differentiated 19.3 female pre procedure and pre operative covid 23.6 adenocarcinoma right 31 female pre procedure and pre operative covid 23.6 adenocarcinoma right 34 pT2 moderately differentiated 35 female pre procedure and pre operative covid 25.1 squamous cell carcinoma right 0.4 moderately differentiated 35 female expedited covid19 23.68 neuroendocrine carcinoma right 6 pT3 poorly differentiated 36 female expedited covid 28.3 adenocarcinoma right 1.5 pT1 moderately differentiated 37 female coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma right 4.5 pT4 moderately differentiated 38 female covid19 coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma right 4.5 pT4 moderately differentiated 40 male two coronavirus (sars cov 2 access labs) 28 mucinous adenocarcinoma right 4.5 pT3 well differentiated 40 male two coronavirus (sars cov 2 access labs) 28 mucinous adenocarcinoma right 4.5 pT3 moderately differentiated 42 female coronavirus (sars cov 2 access labs) 27.1 squamous cell carcinoma right 0.7 pT2 moderately differentiated 42 female coronavirus (sars cov 2 access labs) 27.1 squamous cell carcinoma right 0.7 pT2 moderately differentiated 42 female coronavirus (sars cov 2 access labs) 27.1 squamous cell carcinoma right 0.7 pT2 moderately differentiated 42 female coronavirus (sars cov 2 access labs) 27.1 squamous cell carcin	GERD GERD GERD Ulcerative Colitis GERD Type II Diabetes Mellitus
27 male pre procedure and pre operative covid 32.2 adenocarcinoma left 1.8 pT2 29 male pre procedure and pre operative covid 36.7 a adenocarcinoma left 1.8 pT2 29 male pre procedure and pre operative covid 30.2 adenocarcinoma left 31 female pre procedure and pre operative covid 30.2 adenocarcinoma left 31 female pre procedure and pre operative covid 31.16 adenocarcinoma left moderately differentiated 32 female pre procedure and pre operative covid 23.6 adenocarcinoma left moderately differentiated 33 female pre procedure and pre operative covid 23.6 adenocarcinoma left moderately differentiated 33 female three pre procedure and pre operative covid 23.6 adenocarcinoma left moderately differentiated 34 male pre procedure and pre operative covid 25.1 squamous cell carcinoma left 0.4 moderately differentiated 35 female expedited covid 25.1 squamous cell carcinoma left 0.4 moderately differentiated 35 female expedited covid 25.3 squamous cell carcinoma right 6 pT3 poorly differentiated 36 female expedited covid 28.3 adenocarcinoma left 1.5 pT1 moderately differentiated 37 female coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma left 5.5 pT3 well differentiated 38 female expedited covid 9.2 3.6 adenocarcinoma left 9.5 pT4 moderately differentiated 38 female expedited covid 9.2 3.6 adenocarcinoma left 9.5 pT3 well differentiated 40 male expedited covid 9.2 2.3 adenocarcinoma left 9.3 pT2 well differentiated 42 female coronavirus (sars cov 2 access lab 30.4 adenocarcinoma left 0.3 pT3 moderately differentiated 42 female coronavirus (sars cov 2 access lab 30.4 adenocarcinoma left 0.7 pT2 moderately differentiated 42 female coronavirus (sars cov 2 access lab 30.4 adenocarcinoma left 0.7 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 0.7 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 0.7 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinom	GERD GERD GERD Ulcerative Colitis GERD Type II Diabetes Mellitus
29 male pre procedure and pre operative covid 36.78 adenocarcinoma right 0.4 pT3 well differentiated 30 male pre procedure and pre operative covid 30.2 adenocarcinoma left 31 female pre procedure and pre operative covid 33.6 adenocarcinoma right 4.5 pT2 moderately differentiated 32 female pre procedure and pre operative covid 23.6 adenocarcinoma left moderately differentiated as female three pre procedure and pre operative covid 19.1 squamous cell carcinoma left 3.4 pT2 moderately differentiated as female expedited covid 2.3 squamous cell carcinoma left 0.4 moderately differentiated as female expedited covid 2.3 squamous cell carcinoma right 6 pT3 poorly differentiated as female expedited covid 2.3 squamous cell carcinoma right 1.5 pT1 moderately differentiated as female expedited covid 2.3 adenocarcinoma right 1.5 pT1 moderately differentiated as female covid 19.2 squamous cell carcinoma right 1.5 pT1 moderately differentiated as female covid 19.2 squamous cell carcinoma right 1.5 pT1 moderately differentiated as female covid 19.2 squamous cell carcinoma left 5.5 pT3 well differentiated as female expedited covid 19.2 squamous cell carcinoma left 3.5 pT2 moderately differentiated 42 female expedited covid 19.2 coronavirus (sars cov 2 access lab) 2.3 adenocarcinoma left 0.3 pT3 moderately differentiated 42 female coronavirus (sars cov 2 access lab) 2.8 mucinous adenocarcinoma left 0.3 pT3 moderately differentiated 42 female coronavirus (sars cov 2 access lab) 2.7.1 squamous cell carcinoma left 0.7 pT2 moderately differentiated 43 male pre procedure and pre operative covid 2.7.1 squamous cell carcinoma left 0.7 pT2 moderately differentiated 45 male pre procedure and pre operative covid 2.7.1 squamous cell carcinoma left 0.7 pT2 moderately differentiated 45 male pre procedure and pre operative covid 2.7.1 squamous cell carcinoma left 0.7 pT2 moderately differentiated 45 male pre procedure and pre operative covid 2.7.1 squamous cell carcinoma left 0.7 pT2 moderately differentiated 45 male pre precedure and pre oper	GERD Ulcerative Colitis GERD Type II Diabetes Mellitus GERD
30 male pre procedure and pre operative covid 30.2 adenocarcinoma left 31 female pre procedure and pre operative covid 31.6 adenocarcinoma right 4.5 pT2 moderately differentiated pre procedure and pre operative covid 23.6 adenocarcinoma left moderately differentiated 33 female three pre procedure and pre operative covid 23.6 adenocarcinoma left 3.4 pT2 moderately differentiated 34 male pre procedure and pre operative covid 25.1 squamous cell carcinoma left 0.4 moderately differentiated 35 female expedited covid19 23.68 neuroendocrine carcinoma right 6 pT3 poorly differentiated 36 female expedited covid 25.3 adenocarcinoma right 1.5 pT1 moderately differentiated 27 female coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma right 1.5 pT1 moderately differentiated 38 female covid19 PCR nasopharynx (BIOREF) 23.6 adenocarcinoma left 5.5 pT3 well differentiated 40 male expedited covid19, coronavirus (sars cov 2 access labs) 22.8 adenocarcinoma left 3 pT2 well differentiated 42 female three coronavirus (sars cov 2 access labs) adenocarcinoma left 3.5 pT3 moderately differentiated 42 female coronavirus (sars cov 2 access labs), p 3.0 adenocarcinoma left 0.3 pT3 moderately differentiated 42 female coronavirus (sars cov 2 access labs), p 3.7 adenocarcinoma left 0.7 pT2 moderately differentiated 43 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated	GERD Ulcerative Colitis GERD Type II Diabetes Mellitus GERD
31 female pre procedure and pre operative covid 23.6 adenocarcinoma right 4.5 pT2 moderately differentiated pre procedure and pre operative covid 23.6 adenocarcinoma left moderately differentiated as female pre procedure and pre operative covid 23.6 adenocarcinoma left 3.4 pT2 moderately differentiated pre procedure and pre operative covid 25.1 squamous cell carcinoma left 0.4 moderately differentiated as female expedited covid19 23.68 neuroendocrine carcinoma right 6 pT3 poorly differentiated 23 female expedited covid 28.3 adenocarcinoma right 1.5 pT1 moderately differentiated 37 female coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma right 4.5 pT4 moderately differentiated 38 female covid19 PCR nasopharynx (BIOREF) 23.6 adenocarcinoma left 5.5 pT3 well differentiated 39 female covid19 PCR nasopharynx (BIOREF) 23.6 adenocarcinoma left 5.5 pT3 well differentiated 40 male two coronavirus (sars cov 2 access lab) 28 mucinous adenocarcinoma left 4.5 pT3 moderately differentiated 41 male three coronavirus (sars cov 2 access lab) 28 mucinous adenocarcinoma left 0.3 pT2 well differentiated 42 female coronavirus (sars cov 2 access lab), p 33.2 adenocarcinoma left 0.7 pT2 moderately differentiated 43 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 43 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre precedure and pre operative covid	Ulcerative Colitis GERD Type II Diabetes Mellitus GERD
33 female three pre procedure and pre operative 19.1 squamous cell carcinoma left 3.4 pT2 moderately differentiated 24 male pre procedure and pre operative covid 25.1 squamous cell carcinoma left 0.4 moderately differentiated 35 female expedited covid19 23.68 neuroendocrine carcinoma right 6 pT3 poorly differentiated 36 female expedited covid 28.3 adenocarcinoma right 1.5 pT1 moderately differentiated 37 female coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma right 4.5 pT4 moderately differentiated 38 female covid19 PCR nasopharynx (BIOREF) 23.6 adenocarcinoma left 5.5 pT3 well differentiated 40 male expedited covid19, coronavirus (sars sov 2 access lab: 30.8 adenocarcinoma left 3 pT2 well differentiated 41 male three coronavirus (sars cov 2 access lab: 30.4 adenocarcinoma left 0.3 pT3 moderately differentiated 42 female coronavirus (sars cov 2 access labs), p 33.2 adenocarcinoma left 0.7 pT2 moderately differentiated 42 female pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 43 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated	GERD Type II Diabetes Mellitus GERD
34 male pre procedure and pre operative covid 25.1 squamous cell carcinoma left 0.4 moderately differentiated 35 female expedited covid19 23.68 neuroendocrine carcinoma right 6 pT3 poorly differentiated 36 female coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma right 1.5 pT1 moderately differentiated 37 female coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma right 4.5 pT4 moderately differentiated 38 female covid19 PCR nasopharynx (BIORET) 23.6 adenocarcinoma left 5.5 pT3 well differentiated 40 male two coronavirus (sars cov 2 access lab) 28 mucinous adenocarcinoma left 4.5 pT4 well differentiated 41 male three coronavirus (sars cov 2 access lab) 28 mucinous adenocarcinoma left 4.5 pT3 moderately differentiated 42 female coronavirus (sars cov 2 access lab) 30.4 adenocarcinoma left 0.3 pT3 moderately differentiated 42 female coronavirus (sars cov 2 access lab) 10.4 adenocarcinoma left 0.3 pT3 moderately differentiated 42 female coronavirus (sars cov 2 access lab) 10.4 adenocarcinoma left 0.7 pT2 moderately differentiated 43 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 43 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated 45 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated	GERD Type II Diabetes Mellitus GERD
35 female expedited covid19 23.68 neuroendocrine carcinoma right 6 pT3 poorly differentiated 36 female expedited covid 28.3 adenocarcinoma right 1.5 pT1 moderately differentiated 37 female coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma right 4.5 pT4 moderately differentiated 38 female covid19 PCR nasopharynx (BIOREF) 23.6 adenocarcinoma left 5.5 pT3 well differentiated 39 female expedited covid19, coronavirus (sars 30.8 adenocarcinoma left 3.0 pT2 well differentiated 40 male two coronavirus (sars cov 2 access lab) 28 mucinous adenocarcinoma left 4.5 pT3 41 male three coronavirus (sars cov 2 access lab) 30.4 adenocarcinoma left 0.3 pT3 moderately differentiated 42 female coronavirus (sars cov 2 access labs), p 33.2 adenocarcinoma left 0.7 pT2 moderately differentiated 43 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3.0 pT2 moderately differentiated	GERD Type II Diabetes Mellitus GERD
37 female coronavirus (sars cov 2 access labs) 22.3 adenocarcinoma right 4.5 pT4 moderately differentiated 38 female covid19 PCR nasopharynx (BIOREF) 23.6 adenocarcinoma left 5.5 pT3 well differentiated 5.5 pT3 well differentiated 4.5 pT4 moderately differentiated 4.5 pT3 well differentiated 4.5 pT3 pT2 well differentiated 4.5 pT3 pT3 well differentiated 4.5 pT3 pT3 well differentiated 4.5 pT3	GERD Type II Diabetes Mellitus GERD
38 female covid19 PCR nasopharynx (BIOREF) 23.6 adenocarcinoma left 5.5 pT3 well differentiated 39 female expedited covid19, coronavirus (sars so 2 access lab: 28 mucinous adenocarcinoma left 3 pT2 well differentiated 40 male two coronavirus (sars cov 2 access lab: 28 mucinous adenocarcinoma left 4.5 pT3 41 male three coronavirus (sars cov 2 access lab: 30.4 adenocarcinoma left 0.3 pT3 moderately differentiated 42 female coronavirus (sars cov 2 access labs), p 33.2 adenocarcinoma left 0.7 pT2 moderately differentiated 43 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated	GERD Type II Diabetes Mellitus GERD
39 female expedited covid19, coronavirus (sars 30.8 adenocarcinoma left 3 pT2 well differentiated 40 male two coronavirus (sars cov 2 access lab: 28 mucinous adenocarcinoma left 4.5 pT3 41 male three coronavirus (sars cov 2 access lab: 30.4 adenocarcinoma left 0.3 pT3 moderately differentiated 42 female coronavirus (sars cov 2 access labs), p 33.2 adenocarcinoma left 0.7 pT2 moderately differentiated 43 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated	GERD Type II Diabetes Mellitus GERD
41 male three coronavirus (sars cov 2 access lail) 30.4 adenocarcinoma left 0.3 pT3 moderately differentiated 42 female coronavirus (sars cov 2 access labs), p 33.2 adenocarcinoma left 0.7 pT2 moderately differentiated 43 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated	Type II Diabetes Mellitus GERD
42 female coronavirus (sars cov 2 access labs), p 33.2 adenocarcinoma left 0.7 pT2 moderately differentiated 43 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated	GERD
43 male pre procedure and pre operative covid 27.1 squamous cell carcinoma left 3 pT2 moderately differentiated	
45 male expedited covid19 23.7 adenocarcinoma left 5.5 nT3 moderately differentiated	
46 female expedited covid19 24.24 mucinous adenocarcinoma right 5 pT3 poorly differentiated	GERD GERD
47 female pre procedure and pre operative covid 28.91 adenocarcinoma right 4.5 pT3 moderately differentiated	
48 male expedited covid19 26.1 adenocarcinoma right 1.5 pT2 moderately differentiated	
49 male pre procedure and pre operative covid 26.2 adenocarcinoma left 3 pT3 moderately differentiated 55 male coronavirus (sars cov 2 access labs), ss 24.5 adenocarcinoma left 3.5 pT3 moderately differentiated	Type II Diabetes Mellitus
56 male 2019 coronavirus, two coronavirus (s 30.4 adenocarcinoma right 4 pT2 moderately differentiated	GERD
57 male sars cov 2 rapid result antigen test 26.8 adenocarcinoma left 2.5 pT1 moderately differentiated 58 male expedited covid19 27.12 adenocarcinoma left 3 pT4 moderately differentiated	GERD
58 male expedited covid19 27.12 adenocarcinoma left 3 pT4 moderately differentiated 59 male four sars-cov-2 molecular POCT covid 28.3 adenocarcinoma left 4 pT3 poorly differentiated	GERD
60 male expedited covid19, two sars-cov-2 PCI 28.9 adenocarcinoma left 4 pT3 moderately differentiated	Type II Diabetes Mellitus
61 male pre procedure and pre operative covid 30.4 adenocarcinoma left 4.5 pT2 moderately differentiated 62 female two sars-cov-2 RNA pre procedure and 21.14 adenocarcinoma left 2.5 pT3 moderately differentiated	GERD
64 female 2019 coronavirus, three pre procedur 28.5 adenocarcinoma left 4.5 pT3 poorf differentiated	
66 male two sars-cov-2 RNA, expedited covid1 38.2 adenocarcinoma left 5 pT3 moderately differentiated	Type II Diabetes Mellitus
68 male expedited covid19, pre procedure anc 27.4 adenocarcinoma left 3.5 pT3 moderately differentiated 69 male expedited covid19, 2019 coronavirus 42.8 mucinous adenocarcinoma right 5 pT3 moderately differentiated	GERD
73 female pre procedure and pre operative covid 48 adenocarcinoma left 3 pT2 moderately differentiated	
75 male 2019 coronavirus, pre procedure and 20.5 adenocarcinoma right 7 pT4 well differentiated	CERD
76 male 2019 coronavirus 27.83 adenocarcinoma right 7.5 pT3 moderately differentiated 77 male pre procedure and pre operative covid 24.65 adenocarcinoma left 7 pT4	GERD
79 male sars-cov-2 PCR 21.7 adenocarcinoma left 3.2 pT2 moderately differentiated	
80 female 2019 coronavirus, coronavirus (sars cc 27.21 adenocarcinoma left 2 pT2 moderately differentiated 81 female sars-cov-2 RNA, expedited covid19, ct 24.55 adenocarcinoma left	GERD GERD
84 female sars-cov-2 nova, expected contains, or 24-33 aventual cultures left 7 pT4 poorly differentiated	GEND
85 male pre procedure and pre operative covid 30.5 adenocarcinoma left 4.5 pT2 moderately differentiated	
93 female 2019 coronavirus, pre procedure and 20.98 adenocarcinoma left 6 pT4 moderately differentiated 103 female pre procedure and pre operative covid 19.9 adenocarcinoma left 1.8 pT2 moderately differentiated	GERD
113 male expedited covid19, two sars cov 2 PCF 28.1 adenocarcinoma right 8.5,2 pT3,pT1 moderately differentiated,	well differe Type II Diabetes Mellitus & GERD
114 male expedited covid + flu A/B, four pre prα 31.74 adenocarcinoma right 3.8 pT3 moderately differentiated	GERD
115 male pre procedure and pre operative covid 27.67 adenocarcinoma left 3 pT2 poorty differentiated 117 male pre procedure and pre operative covid 31.31 adenocarcinoma right 4.5 pT4 moderately differentiated	GERD
119 male expedited covid, expedited covid + flu 29.35 adenocarcinoma left 2.5 pT2 poorly differentiated	
121 female expedited covid19 24.4 adenocarcinoma right 4.6 pT3 moderately differentiated 124 male two expedited covid19, 26.23 medullary carcinoma right 11 pT3	
124 male two expedited covid 19, 26,23 mediulary carcinoma right 11 pl 3 126 male 2019 coronavirus, pre operative and g 30 adenocarcinoma left 3.5 pT3 poorly differentiated	type II Diabetes Mellitus & GERD
130 male two expedited covid, 23 adenocarcinoma right 10 pT3 moderately differentiated	
136 female two expedited covid 18.11 adenocarcinoma left 2 pT2 moderately differentiated 137 female pre procedure and pre operative covid 21.8 adenocarcinoma right 1.5 pT1 moderately differentiated	type II Diabetes Mellitus
142 female expedited covid19 24.8 adenocarcinoma right 2.8 pT3 moderately differentiated	
146 male three H&E/HC stains, coronavirus (sa 28.3 adenocarcinoma right 3.5 pT3 moderately differentiated the properties of the properties	CERD
149 male expedited covid19 31.34 adenocarcinoma left 2.5 poorly differentiated 152 male two expedited covid19 23.47 adenocarcinoma left 2 pT3	GERD GERD
153 male two 2019 coronavirus, covid19 PCR ni 27.67 adenocarcinoma left 3.5 pT1 moderately differentiated	
161 female two coronavirus (sars cov 2 access labs) to 24.8 adenocarcinoma left 2.5 pT2 moderately differentiated	GERD GERD
164 remaie coronavirus (sars cov 2 access iasts), ti 24.5 adenocarcinoma lett 2.5 p12 moderately differentiated 172 male per pocedure and pre operative covid 2.07 adenocarcinoma right 2.5 p74	GEND
178 male two expedited covid19, two pre proce 26.05 adenocarcinoma right 6.2 pT4 moderately differentiated	type II Diabetes Mellitus
179 femaleexpedited covid19, pre procedure and26.15 adenocarcinomaleft4 pT4moderately differentiated181 malesars-cov-226.62 adenocarcinomaleft1 pT2moderately differentiated	GERD type II Diabetes Mellitus
181 male safs-cov-2 25.62 adenocarcinoma left 1 pl2 moderately differentiated 182 female expedited covid19, Sars-Cov-2 30.73 squamous collection left 2 poorly differentiated	type ii pianetes ivieilitus
187 male coronavirus (sars cov 2 access labs), e: 24.74 adenocarcinoma left 4.5 pT2 moderately differentiated	GERD
195 male expedited covid19, two covid19 PCR, 18.19 adenocarcinoma left 1.6 pT4 205 male two expedited covid, two coronavirus 34.67 adenocarcinoma right 0.3 moderately differentiated	GERD
206 male 2019 coronavirus, expedited covid19 30.06 squamous cell carcinoma left 10.2 pT3 moderately differentiated	GERD
207 female two CCIRH rapid covid 25.9 adenocarcinoma left 4.1 pT1 moderately differentiated	GERD
208 female expedited covid, pre procedure and p 17.12 adenocarcinoma left 5 pT2 211 male coronavirus (sars cov 2 access lab) pre 21.8 adenocarcinoma left moderately differentiated	GERD
215 male three pre procedure and pre operative 34.31 adenocarcinoma left 6 pT2 moderately differentiated	
217 male expedited covid19, two coronavirus (\$ 22.78 adenocarcinoma left 5 pT4 moderately differentiated 219 male two expedited covid19, 2019 coronav 30.73 squamous cell carcinoma left 4 pT4 moderately differentiated	GERD
219 male two expedited covid19, 2019 coronav 30.73 squamous cell carcinoma left 4 pT4 moderately differentiated 229 male expedited covid19, rapid SARS-COV-2 31.2 adenocarcinoma left 4.5 pT3 moderately differentiated	type II Diabetes Mellitus
239 female pre procedure and pre operative covid 34.57 adenocarcinoma left 0.1 pT1 well differentiated	